Journal article
Sex disparity in secondary prevention pharmacotherapy and clinical outcomes following acute coronary syndrome
M Dagan, DT Dinh, J Stehli, C Tan, A Brennan, J Warren, AE Ajani, M Freeman, A Murphy, CM Reid, C Hiew, E Oqueli, DJ Clark, SJ Duffy
European Heart Journal Quality of Care and Clinical Outcomes | OXFORD UNIV PRESS | Published : 2022
Abstract
Aims: We sought to investigate if sex disparity exists for secondary prevention pharmacotherapy following acute coronary syndrome (ACS) and impact on long-term clinical outcomes. Methods and results: We analysed data on medical management 30-day post-percutaneous coronary intervention (PCI) for ACS in 20 976 patients within the multicentre Melbourne Interventional Group registry (2005-2017). Optimal medical therapy (OMT) was defined as five guideline-recommended medications, near-optimal medical therapy (NMT) as four medications, sub-optimal medical therapy (SMT) as ≤3 medications. Overall, 65% of patients received OMT, 27% NMT and 8% SMT. Mean age was 64 ± 12 years; 24% (4931) were female. ..
View full abstractGrants
Awarded by Bristol-Myers Squibb
Funding Acknowledgements
The Melbourne Interventional Group gratefully acknowledges funding from: Abbott Vascular, Astra-Zeneca, BMS and Pfizer. These companies do not have access to data and do not have the right to review manuscripts or abstracts before publication. C.M.R. is supported by a National Health and Medical Research Council of Australia Principal Research Fellowship (reference no. 11136372). S.J.D. work is supported by a National Health and Medical Research Council of grant (reference no. 1111170).